Jefim Brodkin

Jefim Brodkin

Auto-generated profile, based on publicly available information

Jefim Brodkin

Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2024 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JBJefim Brodkin
Jefim Brodkin
TKTuomas Kaprio
Tuomas Kaprio
JHJaana Hagström
Jaana Hagström
ALAlli Leppä
Alli Leppä
AKArto Kokkola
Arto Kokkola
CBCamilla Böckelman
Camilla Böckelman
Introduction: Gastric cancer is the fifth most common cancer worldwide and the fourth most common cause of cancer-related death. Two molecular subtyping classifications were recently introduced: The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) classifications. Methods: We classified a cohort of 283 gastric cancer patients undergoing surgery at Helsinki University Hospital between 2000 and 2009. We constructed a tumour tissue microarray immunostained for the following markers: microsatellite instability (MSI) markers MSH2, MSH6, MLH1, and PMS2; p53; E-cadherin; and EBERISH. Results: In the univariate survival analysis for disease-specific survival, the Epstein–Barr virus (EBV) -positive subtype exhibited the worst prognosis with a hazard ratio (HR) of 2.49 (95% confidence interval [CI] 1.19–5.25, p = 0.016) compared with the most benign subtype, chromosomal instability (CIN). Using TCGA’s classification, the genetically stable (GS) and MSI subtypes exhibited a worse survival compared with CIN (HR 1.73 [95% CI 1.15–2.60], p = 0.009 and HR 1.74 [95% CI 1.06–2.84], p = 0.027, respectively). Using the ACRG classification, the p53 aberrant subtype exhibited the best prognosis, whereas wild-type p53, MSI, and the epithelial–mesenchymal transition (EMT) subtypes exhibited poorer prognoses (EMT: HR 1.90 [95% CI 1.30–2.77], p < 0.001) when compared with aberrant p53. Conclusions: Immunohistochemical analysis can identify prognostically different molecular subtypes of gastric cancer. The method is inexpensive and fast, yet reveals significant information for clinical decision-making. However, our study did not find that either molecular subtyping performed better than the other classification. Thus, further development of the most optimal grouping of different molecular subtypes is still needed.

15 June 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
PKPauliina Kallio
Pauliina Kallio
EJElina Jokinen
Elina Jokinen
JHJenny Högström
Jenny Högström
SDSuvendu Das
Suvendu Das
SHSarika Heino
Sarika Heino
KAKari Alitalo
Kari Alitalo
Abnormal vasculature in tumors leads to poor tissue perfusion and cytostatic drug delivery. Although drugs inducing vascular normalization, for example, angiopoietin-2 (Ang2)-blocking antibodies, have shown promising results in preclinical tumor models, clinical studies have so far shown only little efficacy. Because Ang2 is known to play a protective role in stressed endothelial cells, we tested here whether Ang2 blocking could enhance radiation-induced tumor vascular damage. Tumor-bearing mice were treated with anti-Ang2 antibodies every 3 or 4 days starting 3 days before 3 × 2 Gy or 4 × 0.5 Gy whole-body or tumor-focused radiation. Combination treatment with anti-Ang2 and radiation improved tumor growth inhibition and extended the survival of mice with melanoma or colorectal tumors. Single-cell RNA-sequencing revealed that Ang2 blocking rescued radiation-induced decreases in T cells and cells of the monocyte/macrophage lineage. In addition, anti-Ang2 enhanced radiation-induced apoptosis in cultured endothelial cells. In vivo, combination treatment decreased tumor vasculature and increased tumor necrosis in comparison with tumors treated with monotherapies. These results suggest that a combination of Ang2-blocking antibodies with radiation increases tumor growth inhibition and extends the survival of tumor-bearing mice. Significance: These findings offer a preclinical rationale for further testing of the use of radiation in combination with Ang2-blocking antibodies to improve the overall outcome of cancer treatment.

29 March 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JBJefim Brodkin
Jefim Brodkin
TKTuomas Kaprio
Tuomas Kaprio
HMHarri Mustonen
Harri Mustonen
ALAlli Leppä
Alli Leppä
AKArto Kokkola
Arto Kokkola
CBCamilla Böckelman
Camilla Böckelman
Gastric cancer is the fifth most common cancer and the fifth leading cause of cancer-related death worldwide. Its poor prognosis primarily results from a late diagnosis and the lack of effective treatments for advanced disease. Thus, we aimed to identify new prognostic serum biomarkers to aid clinical decision-making. Our patient cohort consisted of 240 individuals who underwent surgery for histologically verified gastric adenocarcinoma in the Department of Surgery at Helsinki University Hospital between 2000 and 2009. To determine the serum protein concentrations of cytokines and growth factors, we utilized Bio-Rad’s premixed Bio-Plex Pro Human Cytokine 27- and 21-plex assay kits. Among the 48 biomarkers we analyzed, three emerged as statistically significant prognostic markers for disease-specific survival using the Cox proportional hazards univariate analysis: C-X-C motif chemokine ligand 12 (CXCL12) (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.23–0.63, p < 0.001), stem cell factor (HR 0.38, 95% CI 0.19–0.77, p = 0.007), and eotaxin (HR 0.57, 95% CI 0.37–0.89, p = 0.013). Our multivariate survival analysis revealed that, among the 48 biomarkers analyzed, CXCL12 and eotaxin served as independent prognostic markers among gastric cancer patients. The prognostic effect of inflammatory serum biomarkers in gastric cancer may provide new insights into the immunological microenvironment of disease.

22 January 2025 in Cancer Research
Verified
Journal Article
Open access
PKPauliina Kallio
Pauliina Kallio
CBCinzia Bessone
Cinzia Bessone
FSFatemeh Seyednasrollah
Fatemeh Seyednasrollah
JBJefim Brodkin
Jefim Brodkin
MLMarika Lassila
Marika Lassila
KAKari Alitalo
Kari Alitalo
Colorectal cancer progression is associated with an increase in PROX1+ tumor cells, which exhibit features of colorectal cancer stem cells and contribute to metastasis. Here, we aimed to provide a better understanding of the function of PROX1+ cells in colorectal cancer, investigating their progeny and their role in therapy resistance. PROX1+ cells in intestinal adenomas of ApcMin/+ mice expressed intestinal epithelial and colorectal cancer stem cell markers, and cells with high PROX1 expression could both self-renew tumor stem/progenitor cells and contribute to differentiated tumor cells. Most Prox1 lineage–traced tumor cells were stem/progenitor cells, which can supply cells to multiple intestinal tumor cell lineages, whereas most lineage-traced Lgr5+ tumor cells were enterocytes, indicating that Prox1+ and Lgr5+ tumor stem cells have distinct differentiation programs. Although the PROX1+ tumor cells proliferated slower than PROX1− cells, irradiation increased the proportion of PROX1+ cells in human colorectal cancer cell lines, patient-derived organoids, and tumor xenografts. Furthermore, transcripts related to DNA damage repair (DDR) were enriched in PROX1+ versus PROX1− cells in adenomas and in colorectal cancer tumor cells from patients. Experiments with PROX1 silencing and overexpression indicated that PROX1 expression enhances colorectal cancer cell colony formation following irradiation. PROX1 interacted with DDR proteins, including components of nonhomologous end joining (NHEJ) and base excision repair, and inhibition of NHEJ repair led to a decreased proportion of PROX1+ cells following irradiation. In conclusion, PROX1+ cells are irradiation-resistant tumor stem/progenitor cells capable of self-renewal and differentiation. DDR inhibitors could represent a strategy to target the treatment-resistant PROX1+ tumor stem cells. Significance: Colorectal cancer stem/progenitor cells expressing the PROX1 transcription factor display increased radiation resistance, which may be targeted by small-molecule inhibitors of the nonhomologous end-joining DNA damage repair pathway.

1 December 2025
Verified
Other
Open access
PKPauliina Kallio
Pauliina Kallio
CBCinzia Bessone
Cinzia Bessone
FSFatemeh Seyednasrollah
Fatemeh Seyednasrollah
JBJefim Brodkin
Jefim Brodkin
MLMarika Lassila
Marika Lassila
KAKari Alitalo
Kari Alitalo
Colorectal cancer progression is associated with an increase in PROX1+ tumor cells, which exhibit features of colorectal cancer stem cells and contribute to metastasis. Here, we aimed to provide a better understanding of the function of PROX1+ cells in colorectal cancer, investigating their progeny and their role in therapy resistance. PROX1+ cells in intestinal adenomas of ApcMin/+ mice expressed intestinal epithelial and colorectal cancer stem cell markers, and cells with high PROX1 expression could both self-renew tumor stem/progenitor cells and contribute to differentiated tumor cells. Most Prox1 lineage–traced tumor cells were stem/progenitor cells, which can supply cells to multiple intestinal tumor cell lineages, whereas most lineage-traced Lgr5+ tumor cells were enterocytes, indicating that Prox1+ and Lgr5+ tumor stem cells have distinct differentiation programs. Although the PROX1+ tumor cells proliferated slower than PROX1− cells, irradiation increased the proportion of PROX1+ cells in human colorectal cancer cell lines, patient-derived organoids, and tumor xenografts. Furthermore, transcripts related to DNA damage repair (DDR) were enriched in PROX1+ versus PROX1− cells in adenomas and in colorectal cancer tumor cells from patients. Experiments with PROX1 silencing and overexpression indicated that PROX1 expression enhances colorectal cancer cell colony formation following irradiation. PROX1 interacted with DDR proteins, including components of nonhomologous end joining (NHEJ) and base excision repair, and inhibition of NHEJ repair led to a decreased proportion of PROX1+ cells following irradiation. In conclusion, PROX1+ cells are irradiation-resistant tumor stem/progenitor cells capable of self-renewal and differentiation. DDR inhibitors could represent a strategy to target the treatment-resistant PROX1+ tumor stem cells.Significance:Colorectal cancer stem/progenitor cells expressing the PROX1 transcription factor display increased radiation resistance, which may be targeted by small-molecule inhibitors of the nonhomologous end-joining DNA damage repair pathway.

31 March 2023
Verified
Other
Open access
PKPauliina Kallio
Pauliina Kallio
EJElina Jokinen
Elina Jokinen
JHJenny Högström
Jenny Högström
SDSuvendu Das
Suvendu Das
SHSarika Heino
Sarika Heino
KAKari Alitalo
Kari Alitalo